"The World Stroke Organization reports that "Stroke has already reached epidemic proportions. Globally 1 in 4 adults over the age of 25 will have a stroke in their lifetime. 12.2 million people worldwide will have their first stroke this year and 6.5 million will die as a result. Over 110 million people in the world have experienced stroke." Ischemic strokes are the most common type of stroke, with about 87% of all strokes being ischemic strokes. This new volume helps to address this epidemic by presenting detailed studies on ischemic injury, with emphasis on the molecular-level mechanisms and the role of signaling pathways in the body, their structure, and their mechanism of action. The book focuses on molecular pharmacology plans and explains the new areas of research on the discovery of new therapeutic molecules that can be used for combating this life-threatening disease. The significant etiologies of ischemic and hemorrhagic stroke are reviewed in detail. The authors discuss stroke occurrence at different stages of life, such as sex-based differences in the treatment of ischemic injury. The COVID-19 pandemic has created an elevated incidence and risk of ischemic stroke, which is addressed in the volume. The authors cover aspects of the clinical treatment and diagnosis of patients with cardiovascular events, including in-depth information on the prevention, evaluation, therapy selection, result projection, and long-term course of the disease in affected patients. The authors describe the effect of stroke in daily life as well as complications for prevention of stroke. They also detail the involvement of platelets, neurotransmitters, renin-angiotensin-aldosterone system, and vitamin-D in ischemic injury. This book outlines the various aspects of recognizable proof of preclinical and clinical improvement This book also looks at the pharmacological aspects that incorporate physiology of a disease, receptor-connected intracellular weak structure, different transduction pathways, and multiple I/R injuries. Medical researchers, medical students, and medical and neurology residents who handle patients with acute stroke syndromes will find this volume to be a valuable resource. The book will be important to experts on the cutting-edge of molecular pharmacology, detailing the most recent improvements in cell and receptors pharmacology with a noteworthy emphasis on the system of activity of novel medications being worked on for ischemic injury"--
Discuses studies on ischemic injury, emphasising the molecular-level mechanisms and the role, structure and mechanism of signaling pathways in the body. It also explains research on various important topics including new therapeutic molecules to combat this disease, etiologies of ischemic and hemorrhagic stroke, complications etc.
The World Stroke Organization reports that stroke has already reached epidemic proportions. Globally1 in 4 adults over the age of 25 will have a stroke in their lifetime. 12.2 million people worldwide will have their first stroke this year, and 6.5 million will die as a result. Ischemic strokes are the most common type of stroke, with about 87% of all strokes being ischemic strokes.
This new volume addresses this epidemic by presenting detailed studies on ischemic injury, with emphasis on the molecular-level mechanisms and the role of signaling pathways in the body, their structure, and their mechanism of action. The book focuses on molecular pharmacology plans and explains the new areas of research on the discovery of therapeutic molecules that can be used for combating this life-threatening disease. The authors discuss stroke occurrence at different stages of life as well as sex-based differences in its treatment. They cover aspects of the clinical treatment and diagnosis of patients with cardiovascular events, including in-depth information on the prevention, evaluation, therapy selection, result projection, and long-term course of the disease in affected patients. They also detail the involvement of platelets, neurotransmitters, renin-angiotensin-aldosterone system, and vitamin D in ischemic injury.
1. Stroke Insight
2. Myocardial Ischemic-Reperfusion Injury
3. Preclinical and Clinical Aspects of I-R Injuries
4. Molecular Aspects of Ischemic-Reperfusion Injury
5. Role of Mitochondria in Ischemic-Reperfusion Injury
6. Stroke Effect in Daily Life and Therapeutics, Complications for Prevention of Stroke
7. Etiopathogenesis and Molecular Targets in Cerebral Ischemia: Current Understanding of Stroke and Therapeutic Approaches
8. Expatiating the Pivotal Role of Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Ischemic Stroke: Molecular Insights and Therapeutic Targets
9. Acute Ischemic Stroke in COVID-19 Patients
10. Neurotransmission Imbalance: A Major Factor in the Worsening of Ischemic Injury
11. Role of the Renin-Angiotensin-Aldosterone System (RAAS) in Amelioration of Stroke Pathophysiology
12. Stroke and Diabetes in Vitamin D Deficiency: Prospects of Intertwined Pathobiologies
13. Remote Ischemic Post-Conditioning: An Overview
14. Sex-Based Differences in Acute Kidney Injury: Lessons from Renal Ischemia-Reperfusion Injury Model in Rodents
15. Critical Overview of Conditioning Techniques and Their Current Status in the Treatment of Myocardial Ischemia-Reperfusion Injury
16. Involvement of Platelets in Myocardial Ischemia and Reperfusion Injury
17. Recent Advancements in Strategies for Treatment of Cerebral Ischemia
18. Recent Therapeutic Approaches Toward the Management of Ischemic Heart Disease
19. Nanotechnology-Assisted Treatment for Ischemic Heart Disease and Recent Patents
20. Major Risk Factors Involved in the Pathobiology of Ischemic Brain and Heart Disorders
21. Modulating Mitogen-Activated Protein Kinase (MAPK) Downstream Signaling Pathways in Cerebral Ischemic Hemorrhages
22. Implication of Mitogen-Activated Protein Kinase (MAPK) in Cerebral Stroke
23. Regulation of JNK Signaling Pathway in Ischemia-Reperfusion Injury
24. Role of Glycogen Synthase Kinase-3? (Gsk-3?) in Intracranial Haemorrhage
25. Role of GSK-3 Inhibition in Modulating the Pathology of Stroke
26. Regulation of NRF-2 Signaling Pathway in Ischemia-Reperfusion Injury
27. Regulation of PI3K-AKT Signaling Pathway in Ischemia-Reperfusion Injury
28. COVID-19 and Ischemic Stroke: Advancements and Challenges
Thakur Gurjeet Singh, PhD, MPharm, has 16 years of experience in industry, research, and teaching. He is currently Dean of the Chitkara College of Pharmacy, Chitkara University, Punjab, India. He is engaged with projects on interception of nicotine, morphine, alcohol dependence, ischemia, diabetic neuropathy and nephropathy toxicology, epilepsy, Alzheimers disease, and stem cell research studies. He has attended UGC networking courses and various preclinical and clinical research training programs. A prolific author and researcher, he has many publications and patents to his credit. He has attended national and international conferences and has guided MPharm and PhD students. He is a reviewer for various highly reputed international journals. Dr. Singh is a member secretary of the Committee for the Purpose of Control and Supervision of Experiments on Animals and is the In-Charge of the animal house facility at the Chitkara College of Pharmacy.
Heena Khan, PhD, MPharm, has over five years of experience in research. She is working as a Research Fellow at Chitkara University, Punjab, India, where she is engaged with several projects on stroke, diabetes, Alzheimers disease, and Parkinsons disease. She has more than 30 research and review publications to her credit and is a reviewer for several international journals. She has participated and attended several national and international conferences. She is also a member of the International Society for Pharmacoeconomics and Outcomes Research.
Biežāk uzdotie jautājumi par e-grāmatām